Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (CUE) on July 27, 2026. The report discloses the appointment of a new Chief Financial Officer (CFO) and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of James Ahlers as Chief Financial Officer, effective July 30, 2026. Mr. Ahlers will serve as the Company's principal financial officer. He brings extensive experience from roles at Intarcia Therapeutics, Danforth Advisors, Intensity Therapeutics, and RenovoRx.
Compensation and Employment Terms
- Base Salary: $450,000 annualized.
- Annual Bonus: Discretionary target of up to 45% of base salary based on key performance indicators.
- Equity Grants:
- 51,000 nonstatutory stock options (exercise price: $30.40 per share).
- 25,500 restricted stock units (RSUs).
- Vesting: Equal quarterly installments over four years, subject to continued service.
- Severance (Qualifying Termination):
- Lump sum cash equal to nine months of base salary plus prorated target bonus.
- Continued health/dental premium payments for up to nine months.
- Change in Control: Full acceleration of time-vesting equity awards and deemed satisfaction of performance goals (at greater of target or actual) if termination occurs within 90 days prior to or 24 months following a change in control.
Risks and Contingencies
The Company has entered into a standard indemnification agreement with Mr. Ahlers, which may require the Company to indemnify him for expenses, judgments, penalties, fines, and settlement amounts arising from his service as an officer. The full text of the employment agreement will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
Investor Verification Checklist
- Verify the stock price of $30.40 on July 30, 2026, to confirm the option exercise price.
- Review the upcoming Form 10-Q (Q3 2026) for the full text of the Ahlers Employment Agreement.
- Monitor future filings for any changes to the Board of Directors or additional executive appointments.
- Assess the impact of the new CFO's background on the Company's financial strategy and capital raising efforts.